Zengren Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zengren Zhao has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
- Anna Ljusberg
Center for Medical Image Science and Visualization' (CMIV), Linköping University, Linköping, Sweden
79 shared publications - Bin Luo
Sichuan Academy of Medical Sciences and Sichuan People's Hospital
79 shared publications - Carolin Jönsson
Department of Oncology and Department of Biomedical and Clinical Science, Linköping University, Linköping, Sweden
79 shared publications - Chuanwen Fan
Department of Gastrointestinal, Bariatric and Metabolic Surgery, Research Center for Nutrition, Metabolism & Food Safety, West China-PUMC C.C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China
79 shared publications - Jing Zhang
Department of Pathology, the First Hospital of Hebei Medical University, Hebei, China
79 shared publications - Jonas Burman
Departments of Pediatrics and Cell and Developmental Biology, Children’s Cancer and Blood Foundation Laboratories, Drukier Institute for Children’s Health, Meyer Cancer Center Weill Cornell Medicine, New York, USA
79 shared publications
Latest Publications
- 17 November 2026
- Published by ICJN Publishing
- Vol. 1 (2)
The Gut Microbiota in Aging: From Compositional Shifts to Therapeutic Opportunities
Population aging is accelerating worldwide, creating an urgent need to understand biological processes that influence late-life health. The gut microbiota, defined here primarily as the bacterial communities inhabiting the intestine, changes across the lifespan and may contribute to immune, metabolic, neural, and musculoskeletal phenotypes of aging. However, reported age-related microbiota signatures remain heterogeneous, reflecting differences in cohort design, sequencing strategy, functional annotation, and clinical context. In this review, we synthesize evidence from human cohorts, animal models, and mechanistic studies on the bidirectional relationship between host aging and gut microbial remodeling. A central theme is that host factors such as immune senescence, barrier dysfunction, altered gastrointestinal physiology, and medication exposure can drive microbial change. In contrast, microbial products can feed back on aging tissues. We distinguish chronological aging, healthy aging, frailty, exceptional longevity, and age-related diseases, and we evaluate how diet, medication exposure, living environment, geography, and disease burden shape reported microbiota signatures. We further organize microbial functions around metabolite-centered pathways, including short-chain fatty acids, trimethylamine N-oxide, phenylacetylglutamine, bile acids, tryptophan derivatives, and uremic microbial toxins. This framework clarifies when microbial alterations should be interpreted as biomarkers, plausible mediators, or candidate therapeutic targets. Finally, we discuss microbiota-targeted interventions, including diet, prebiotics, probiotics, fecal microbiota transplantation, postbiotics, metabolite-based therapeutics, and phage-based strategies, while emphasizing current limits in causal inference, safety, biomarker validation, and clinical implementation.
- 17 November 2026
- Published by ICJN Publishing
- Vol. 1 (2)
The Gut Microbiota in Aging: From Compositional Shifts to Therapeutic Opportunities
Population aging is accelerating worldwide, creating an urgent need to understand biological processes that influence late-life health. The gut microbiota, defined here primarily as the bacterial communities inhabiting the intestine, changes across the lifespan and may contribute to immune, metabolic, neural, and musculoskeletal phenotypes of aging. However, reported age-related microbiota signatures remain heterogeneous, reflecting differences in cohort design, sequencing strategy, functional annotation, and clinical context. In this review, we synthesize evidence from human cohorts, animal models, and mechanistic studies on the bidirectional relationship between host aging and gut microbial remodeling. A central theme is that host factors such as immune senescence, barrier dysfunction, altered gastrointestinal physiology, and medication exposure can drive microbial change. In contrast, microbial products can feed back on aging tissues. We distinguish chronological aging, healthy aging, frailty, exceptional longevity, and age-related diseases, and we evaluate how diet, medication exposure, living environment, geography, and disease burden shape reported microbiota signatures. We further organize microbial functions around metabolite-centered pathways, including short-chain fatty acids, trimethylamine N-oxide, phenylacetylglutamine, bile acids, tryptophan derivatives, and uremic microbial toxins. This framework clarifies when microbial alterations should be interpreted as biomarkers, plausible mediators, or candidate therapeutic targets. Finally, we discuss microbiota-targeted interventions, including diet, prebiotics, probiotics, fecal microbiota transplantation, postbiotics, metabolite-based therapeutics, and phage-based strategies, while emphasizing current limits in causal inference, safety, biomarker validation, and clinical implementation.
- Open Access
- 6 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1857797
Mechanism of Icariin induces mitochondrial-mediated apoptosis by Wnt/β-catenin signaling pathway in colorectal cancer
Background: To evaluate the effect of Icariin (ICA) on AOM/DSS-induced colorectal cancer (CRC) in mice as well as CRC cells, and to explore the underlying molecular mechanism. Methods: The therapeutic efficacy of ICA against AOM/DSS-induced CRC was evaluated by detecting tumor growth and pathological alterations. Biomarkers related to Wnt/β-catenin and mitochondrial apoptosis were tested, and cell experiments were performed to validate the regulatory correlation between ICA and the Wnt/β-catenin pathway in CRC cells. Results: ICA significantly reduced tumor number, size and ameliorated pathological damage in AOM/DSS-induced mice by regulating the mitochondrial-mediated apoptosis of colon tissue. ICA’s regulation of mitochondrial-mediated apoptosis was confirmed to involve the Wnt/β-catenin signaling pathway. In vitro , ICA restrained proliferation, migration and invasion of SW1463 and HCT116 cells, decreased mitochondrial membrane potential and changed the expression of pathway-related genes. Conclusion: The study demonstrated that ICA promoted mitochondrial-mediated apoptosis by regulating the Wnt/β-catenin signaling pathway, suggesting that ICA could serve as a potential treatment for CRC.
- 6 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1857797
Open AccessMechanism of Icariin induces mitochondrial-mediated apoptosis by Wnt/β-catenin signaling pathway in colorectal cancer
Background: To evaluate the effect of Icariin (ICA) on AOM/DSS-induced colorectal cancer (CRC) in mice as well as CRC cells, and to explore the underlying molecular mechanism. Methods: The therapeutic efficacy of ICA against AOM/DSS-induced CRC was evaluated by detecting tumor growth and pathological alterations. Biomarkers related to Wnt/β-catenin and mitochondrial apoptosis were tested, and cell experiments were performed to validate the regulatory correlation between ICA and the Wnt/β-catenin pathway in CRC cells. Results: ICA significantly reduced tumor number, size and ameliorated pathological damage in AOM/DSS-induced mice by regulating the mitochondrial-mediated apoptosis of colon tissue. ICA’s regulation of mitochondrial-mediated apoptosis was confirmed to involve the Wnt/β-catenin signaling pathway. In vitro , ICA restrained proliferation, migration and invasion of SW1463 and HCT116 cells, decreased mitochondrial membrane potential and changed the expression of pathway-related genes. Conclusion: The study demonstrated that ICA promoted mitochondrial-mediated apoptosis by regulating the Wnt/β-catenin signaling pathway, suggesting that ICA could serve as a potential treatment for CRC.
- Open Access
- 20 May 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Roles of m6A regulators in shaping methylation patterns and tumor microenvironment immune infiltration in colorectal cancer
Recent studies have demonstrated that immune responses are subject to epigenetic regulation. However, the functional roles of RNA N6-methyladenosine (m6A) modification in infiltrating cells within the tumor microenvironment (TME) remain incompletely understood. To systematically characterize m6A modification patterns, we conducted a comprehensive analysis across 1,195 colorectal cancer samples, focusing on 27 m6A regulators. We further associated the three identified modification patterns with the characteristics of immune cell infiltration in the TME. To quantify m6A modification patterns at the individual tumor level, we developed an m6A score using principal component analysis (PCA). Analysis of immune cell infiltration in the TME revealed that the three distinct m6A modification patterns were significantly associated with three tumor immune phenotypes: immune-excluded, immune-inflamed, and immune-desert. Furthermore, univariate and multivariate Cox regression analyses indicated that the m6A score served as an independent and reliable prognostic biomarker for colorectal cancer (CRC) patients. Collectively, these findings suggest that m6A modification is associated with immune modulation and correlates with TME heterogeneity. Characterization of m6A modification patterns in CRC patients may enhance our understanding of immune cell infiltration within the TME and inform immunotherapeutic strategies.
- 20 May 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessRoles of m6A regulators in shaping methylation patterns and tumor microenvironment immune infiltration in colorectal cancer
Recent studies have demonstrated that immune responses are subject to epigenetic regulation. However, the functional roles of RNA N6-methyladenosine (m6A) modification in infiltrating cells within the tumor microenvironment (TME) remain incompletely understood. To systematically characterize m6A modification patterns, we conducted a comprehensive analysis across 1,195 colorectal cancer samples, focusing on 27 m6A regulators. We further associated the three identified modification patterns with the characteristics of immune cell infiltration in the TME. To quantify m6A modification patterns at the individual tumor level, we developed an m6A score using principal component analysis (PCA). Analysis of immune cell infiltration in the TME revealed that the three distinct m6A modification patterns were significantly associated with three tumor immune phenotypes: immune-excluded, immune-inflamed, and immune-desert. Furthermore, univariate and multivariate Cox regression analyses indicated that the m6A score served as an independent and reliable prognostic biomarker for colorectal cancer (CRC) patients. Collectively, these findings suggest that m6A modification is associated with immune modulation and correlates with TME heterogeneity. Characterization of m6A modification patterns in CRC patients may enhance our understanding of immune cell infiltration within the TME and inform immunotherapeutic strategies.
- Top Cited PapersOpen Access
- 7 May 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e92680
From Pilot Trap to Institutional Capacity: A Governance Framework for Sustainable Clinical AI Implementation in Health Systems
Clinical artificial intelligence (AI) applications frequently fail to transition from short-term pilot projects into sustained components of routine clinical care, a phenomenon referred to in this viewpoint as the pilot trap. This persistent gap reflects not only technical or regulatory limitations but also insufficient governance capacity within health care organizations. We argue that such capacity is not fully established before deployment; rather, it develops through implementation as real-world operational tensions clarify organizational ownership, accountability boundaries, and coordination mechanisms. Drawing on an 18-month implementation of a provincial clinical AI platform in China, we develop a 6-module governance framework encompassing institutional carrier formation, infrastructure governance, regulatory and ethical governance, interdisciplinary coordination, translational scaling, and lifecycle evaluation and oversight. These modules represent functional governance conditions observed during implementation rather than a prescriptive institutional architecture to be installed prior to deployment. We further introduce the concept of functional transferability and position the framework as an upstream complement to existing international governance standards, which typically specify what governance should achieve, but often assume that the organizational capacity to implement it already exists. Advancing clinical AI beyond demonstration, therefore, depends less on model performance alone than on the ability of health systems to develop and sustain the institutional capacity required for routine clinical use.
- 7 May 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e92680
Top Cited PapersOpen AccessFrom Pilot Trap to Institutional Capacity: A Governance Framework for Sustainable Clinical AI Implementation in Health Systems
Clinical artificial intelligence (AI) applications frequently fail to transition from short-term pilot projects into sustained components of routine clinical care, a phenomenon referred to in this viewpoint as the pilot trap. This persistent gap reflects not only technical or regulatory limitations but also insufficient governance capacity within health care organizations. We argue that such capacity is not fully established before deployment; rather, it develops through implementation as real-world operational tensions clarify organizational ownership, accountability boundaries, and coordination mechanisms. Drawing on an 18-month implementation of a provincial clinical AI platform in China, we develop a 6-module governance framework encompassing institutional carrier formation, infrastructure governance, regulatory and ethical governance, interdisciplinary coordination, translational scaling, and lifecycle evaluation and oversight. These modules represent functional governance conditions observed during implementation rather than a prescriptive institutional architecture to be installed prior to deployment. We further introduce the concept of functional transferability and position the framework as an upstream complement to existing international governance standards, which typically specify what governance should achieve, but often assume that the organizational capacity to implement it already exists. Advancing clinical AI beyond demonstration, therefore, depends less on model performance alone than on the ability of health systems to develop and sustain the institutional capacity required for routine clinical use.
- Open Access
- 25 February 2026
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Intractable & Rare Diseases Research
- Vol. 15 (1) , 95-105
Comparative analysis of adverse event reporting signals between Satralizumab and Inebilizumab in neuromyelitis optica spectrum disorder: A pharmacovigilance study using the FDA Adverse Event Reporting System
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune disorder predominantly driven by anti-aquaporin-4 immunoglobulin G (AQP4-IgG), which mediates astrocyte injury, neuroinflammation, and demyelination. Satralizumab and Inebilizumab represent two promising therapeutic options with distinct mechanisms of action and clinical profiles. This study conducted a retrospective pharmacovigilance analysis of data from the U.S. FDA Adverse Event Reporting System (FAERS) from January 2020 to June 2025 to assess and compare adverse event (AE) reporting signals associated with Satralizumab and Inebilizumab. The analysis revealed a higher number of reported adverse events for Satralizumab compared to Inebilizumab (1,114 cases vs. 349 cases). A higher reporting proportion of AEs was observed in female patients for both drugs, with no statistically significant difference between them (exploratory p = 0.760). The reported AEs for both agents were primarily categorized under System Organ Classes (SOCs) such as infections and infestations and nervous system disorders. Urinary tract infection and pneumonia were among the most frequently reported preferred terms (PTs) for Satralizumab, whereas headache and COVID-19 were prominent for Inebilizumab. Reports classified as serious were more frequent for Satralizumab than for Inebilizumab (exploratory p < 0.01), noting that "seriousness" in FAERS may encompass outcomes related to underlying disease activity. This signal detection study highlights distinct adverse event reporting profiles for these biologics and offers insights that may inform clinical monitoring and personalized treatment strategies in NMOSD. Further studies with rigorous prospective designs are recommended to validate these findings and elucidate the mechanisms underlying the observed adverse events.
- 25 February 2026
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Intractable & Rare Diseases Research
- Vol. 15 (1) , 95-105
Open AccessComparative analysis of adverse event reporting signals between Satralizumab and Inebilizumab in neuromyelitis optica spectrum disorder: A pharmacovigilance study using the FDA Adverse Event Reporting System
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune disorder predominantly driven by anti-aquaporin-4 immunoglobulin G (AQP4-IgG), which mediates astrocyte injury, neuroinflammation, and demyelination. Satralizumab and Inebilizumab represent two promising therapeutic options with distinct mechanisms of action and clinical profiles. This study conducted a retrospective pharmacovigilance analysis of data from the U.S. FDA Adverse Event Reporting System (FAERS) from January 2020 to June 2025 to assess and compare adverse event (AE) reporting signals associated with Satralizumab and Inebilizumab. The analysis revealed a higher number of reported adverse events for Satralizumab compared to Inebilizumab (1,114 cases vs. 349 cases). A higher reporting proportion of AEs was observed in female patients for both drugs, with no statistically significant difference between them (exploratory p = 0.760). The reported AEs for both agents were primarily categorized under System Organ Classes (SOCs) such as infections and infestations and nervous system disorders. Urinary tract infection and pneumonia were among the most frequently reported preferred terms (PTs) for Satralizumab, whereas headache and COVID-19 were prominent for Inebilizumab. Reports classified as serious were more frequent for Satralizumab than for Inebilizumab (exploratory p < 0.01), noting that "seriousness" in FAERS may encompass outcomes related to underlying disease activity. This signal detection study highlights distinct adverse event reporting profiles for these biologics and offers insights that may inform clinical monitoring and personalized treatment strategies in NMOSD. Further studies with rigorous prospective designs are recommended to validate these findings and elucidate the mechanisms underlying the observed adverse events.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
Figure S6 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
Figure S6 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
Figure S8 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
Figure S8 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
Figure S7 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
Figure S7 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
Figure S9 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
Figure S9 from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
Supplementary Data from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
Supplementary Data from APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy